Skip Navigation


Annals of Oncology Advance Access originally published online on May 12, 2005
Annals of Oncology 2005 16(6):845-846; doi:10.1093/annonc/mdi196
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
16/6/845    most recent
mdi196v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Punt, C. J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Punt, C. J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Editorial

Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?

C. J. A. Punt

Department of Medical Oncology, Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands

Email: c.punt@onco.umcn.nl

The first 10% of the full text of this article appears below.

In this issue of Annals of Oncology, two studies by the Southern Italy Cooperative Oncology Group (SICOG) and the Hellenic Cooperative Oncology Group (HECOG) are presented in which treatment with irinotecan and oxaliplatin, both in combination with 5-fluorouracil/leucovorin (5-FU/LV), is compared in patients with advanced colorectal cancer [1Go, 2Go]. The choice of the first-line regimen may be important, since not all patients are eligible for salvage treatment, which obviously provides a rationale to first administer the most effective treatment. The study by Goldberg et al. [3Go], which showed an overall survival benefit for FOLFOX when compared with IFL, has convinced many colleagues that oxaliplatin should be the preferred choice. However, both the fact that in this study a bolus 5-FU regimen (IFL) was compared with a prolonged 5-FU infusion regimen (FOLFOX), and the fact that . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
D. Arnold, T. Hohler, C. Dittrich, F. Lordick, T. Seufferlein, J. Riemann, E. Woll, T. Herrmann, A. Zubel, and H.-J. Schmoll
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group
Ann. Onc., August 1, 2008; 19(8): 1442 - 1449.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Tabernero, E. Van Cutsem, E. Diaz-Rubio, A. Cervantes, Y. Humblet, T. Andre, J.-L. Van Laethem, P. Soulie, E. Casado, C. Verslype, et al.
Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5225 - 5232.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M Koopman, N. Antonini, J Douma, J Wals, A. Honkoop, F. Erdkamp, R. de Jong, C. Rodenburg, G Vreugdenhil, J. Akkermans-Vogelaar, et al.
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study
Ann. Onc., October 1, 2006; 17(10): 1523 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Meyerhardt, A. X. Zhu, P. C. Enzinger, D. P. Ryan, J. W. Clark, M. H. Kulke, C. C. Earle, M. Vincitore, A. Michelini, S. Sheehan, et al.
Phase II Study of Capecitabine, Oxaliplatin, and Erlotinib in Previously Treated Patients With Metastastic Colorectal Cancer
J. Clin. Oncol., April 20, 2006; 24(12): 1892 - 1897.
[Abstract] [Full Text] [PDF]